Neuroblastoma - Pipeline Review, H1 2020

May 2020 | 915 pages | ID: N440105A463EN
Global Markets Direct

Abstracts

Neuroblastoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma – Pipeline Review, H1 2020, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 39, 20, 4, 45, 11 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 5, 1, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Neuroblastoma - Overview
Neuroblastoma - Therapeutics Development
Neuroblastoma - Therapeutics Assessment
Neuroblastoma - Companies Involved in Therapeutics Development
Neuroblastoma - Drug Profiles
Neuroblastoma - Dormant Projects
Neuroblastoma - Discontinued Products
Neuroblastoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Neuroblastoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H1 2020
Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H1 2020
Neuroblastoma - Pipeline by ADC Therapeutics SA, H1 2020
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H1 2020
Neuroblastoma - Pipeline by Alissa Pharma, H1 2020
Neuroblastoma - Dormant Projects, H1 2020
Neuroblastoma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neuroblastoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Ability Pharmaceuticals SL
Actuate Therapeutics Inc
ADC Therapeutics SA
Advanced Accelerator Applications SA
Alissa Pharma
APEIRON Biologics AG
Aptorum Group Ltd
AstraZeneca Plc
AUM Biosciences Pte Ltd
Autolus Therapeutics Plc
Bayer AG
Bellicum Pharmaceuticals Inc
Bexion Pharmaceuticals LLC
Bio-Cancer Treatment International Ltd
BioEclipse Therapeutics Inc
Biogenera SpA
BioLineRx Ltd
Biotec Pharmacon ASA
BioVec Pharma Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cancer Prevention Pharmaceuticals Inc
Cebiotex SL
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Chiome Bioscience Inc
Clarity Pharmaceuticals Pty Ltd
Cleveland BioLabs Inc
CorMedix Inc
Curis Inc
Cyclacel Pharmaceuticals Inc
DEKK-TEC Inc
Eli Lilly and Co
Epigene Therapeutics Inc
Epizyme Inc
Errant Gene Therapeutics LLC
EUSA Pharma (UK) Ltd
Expression Therapeutics LLC
F. Hoffmann-La Roche Ltd
GC Pharma
Gibson Oncology LLC
Healx Ltd
Hebei Senlang Biotechnology Inc Ltd
Helixmith Co Ltd
HRAIN Biotechnology Co Ltd
Invenra Inc
Ipsen SA
Jubilant DraxImage Inc
Juno Therapeutics Inc
KC Pharma LLC
Kuur Therapeutics Ltd
Lead Discovery Center GmbH
MacroGenics Inc
Mana Therapeutics Inc
MediaPharma SRL
Merck & Co Inc
Millennium Pharmaceuticals Inc
Nanogenics Ltd
NanoPharmaceuticals LLC
Novartis AG
OGD2 Pharma SAS
Ohara Pharmaceutical Co Ltd
Oncology Venture U.S. Inc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Open Therapeutics LLC
Orphelia Pharma SAS
Panorama Research Inc
Pfizer Inc
Progenics Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
PYCTX Ltd
Qualigen Inc
Recombio SL
RedHill Biopharma Ltd
resTORbio Inc
Ribomic Inc
Rophibio Inc
Sapience Therapeutics Inc
SciTech Development LLC
Seneca Therapeutics Inc
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shionogi & Co Ltd
SignalRx Pharmaceuticals Inc
Sinobioway Cell Therapy Co Ltd
SMTPH Ltd
Sorrento Therapeutics Inc
Tactiva Therapeutics LLC
TheraBiologics Inc
Tmunity Therapeutics Inc
Toko Pharmaceutical Industries Co Ltd
Transtarget Inc
Trellis Bioscience Inc
TroBio Therapeutics Pty Ltd
United Therapeutics Corp
Xcovery Holding Co LLC
Y-Biologics Inc
Y-mAbs Therapeutics Inc
ZIOPHARM Oncology Inc